MX2018013215A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2018013215A
MX2018013215A MX2018013215A MX2018013215A MX2018013215A MX 2018013215 A MX2018013215 A MX 2018013215A MX 2018013215 A MX2018013215 A MX 2018013215A MX 2018013215 A MX2018013215 A MX 2018013215A MX 2018013215 A MX2018013215 A MX 2018013215A
Authority
MX
Mexico
Prior art keywords
freeze
pharmaceutical compositions
pharmaceutical composition
antibody
drying
Prior art date
Application number
MX2018013215A
Other languages
English (en)
Inventor
Jeffrey Yates Andrew
Ivo MASSANT Jan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56320265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018013215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2018013215A publication Critical patent/MX2018013215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden un anticuerpo o un fragmento del mismo, adecuadas para el secado por congelación (es decir liofilización). Las composiciones farmacéuticas, que comprenden un anticuerpo o un fragmento de unión al antígeno del mismo; de 1 % a 20 % p/v de sucrosa; un aminoácido o una mezcla de aminoácidos; y un agente tensioactivo, son provistas como composiciones farmacéuticas para el secado por congelación; como composiciones secadas por congelación (es decir liofilizadas) que se pueden reconstituir en un disolvente en el momento del uso o como formulaciones líquidas reconstituidas listas para su administración.
MX2018013215A 2016-05-12 2017-05-11 Composicion farmaceutica. MX2018013215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608323.0A GB201608323D0 (en) 2016-05-12 2016-05-12 Pharmaceutical compositions
PCT/EP2017/061261 WO2017194646A1 (en) 2016-05-12 2017-05-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2018013215A true MX2018013215A (es) 2019-02-21

Family

ID=56320265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013215A MX2018013215A (es) 2016-05-12 2017-05-11 Composicion farmaceutica.

Country Status (17)

Country Link
US (1) US11407835B2 (es)
EP (1) EP3454899B1 (es)
JP (1) JP7126454B2 (es)
KR (1) KR102436694B1 (es)
CN (1) CN109069643A (es)
AR (1) AR108449A1 (es)
AU (1) AU2017264553A1 (es)
BR (1) BR112018072264A2 (es)
CA (1) CA3022124A1 (es)
CL (1) CL2018003178A1 (es)
CO (1) CO2018011733A2 (es)
EA (1) EA201892446A1 (es)
GB (1) GB201608323D0 (es)
IL (1) IL262654A (es)
MX (1) MX2018013215A (es)
SG (1) SG11201809229VA (es)
WO (1) WO2017194646A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
MX2022011248A (es) * 2020-03-11 2022-12-15 Selecta Biosciences Inc Metodos y composiciones relacionados con nanoportadores sinteticos.
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
TW202332471A (zh) 2021-12-01 2023-08-16 比利時商Ｕｃｂ生物製藥公司 調配物
WO2023224112A1 (ja) * 2022-05-20 2023-11-23 株式会社ダイセル 液状医薬組成物
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2004290070A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US8788028B2 (en) 2010-07-28 2014-07-22 Medtronic, Inc. Parasympathetic stimulation to enhance tachyarrhythmia detection
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
KR102031020B1 (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
US20150225479A1 (en) * 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
MX2017004975A (es) 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
CA3022124A1 (en) 2017-11-16
EA201892446A1 (ru) 2019-04-30
CL2018003178A1 (es) 2019-02-01
CO2018011733A2 (es) 2019-02-08
WO2017194646A1 (en) 2017-11-16
JP2019514998A (ja) 2019-06-06
EP3454899A1 (en) 2019-03-20
EP3454899C0 (en) 2024-03-20
JP7126454B2 (ja) 2022-08-26
EP3454899B1 (en) 2024-03-20
AU2017264553A1 (en) 2018-12-13
US11407835B2 (en) 2022-08-09
KR102436694B1 (ko) 2022-08-25
IL262654A (en) 2018-12-31
KR20190008320A (ko) 2019-01-23
RU2018141591A3 (es) 2021-01-13
CN109069643A (zh) 2018-12-21
RU2018141591A (ru) 2020-06-15
US20200048346A1 (en) 2020-02-13
BR112018072264A2 (pt) 2019-02-12
AR108449A1 (es) 2018-08-22
SG11201809229VA (en) 2018-11-29
GB201608323D0 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
MX2018013215A (es) Composicion farmaceutica.
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2023003875A (es) Formulacion de una vacuna peptidica.
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
MX2016006488A (es) Formulacion liofilizada de conjugado de anticuerpo-farmaco.
MX2019005775A (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
BR112016026811A2 (pt) formulação de anticorpo
MX345102B (es) Preparacion liofilizada de dipeptidos citotoxicos.
MX2019000381A (es) Formulacion para la administracion de arn.
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
JP2016520075A5 (es)
BR112018014277A2 (pt) formulação, e, método de preparação de uma solução injetável de um axl-adc
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
WO2015024022A3 (en) Designed peptides for tight junction barrier modulation
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
BR112017013269A2 (pt) ?composição farmacêutica líquida?
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.